Neurofibromatosis and Schwannoma Cases
Neurofibromatosis and Schwannoma Cases is a research topic within Neurology. Science Explorer counts 23k research works in it since 1950. 8.8% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on Neurofibromatosis Type 1 and Type 2, genetic disorders characterized by the development of tumors in the nervous system. The research covers various aspects including the role of tumor suppressor genes, Schwann cell origin of neurofibromas, cognitive deficits associated with the condition, and the molecular mechanisms underlying the disease.
- Neurofibromatosis
- Tumor Suppressor
- Schwann Cells
- Malignant Peripheral Nerve Sheath Tumors
- Gliomas
- Ezrin Protein
- Merlin Protein
- Genetic Mutations
- Cognitive Deficits
- Cell Cortex
- Research works
- 23k fractional, since 1950
- In the world top 10%
- 2k per year above
- Top-10% rate
- 8.8% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +22% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Neurofibromatosis and Schwannoma Cases research?
By volume, the United States and China publish the most (1k and 458 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1k works
- 2 China 458 works
- 3 India 369 works
- 4 Japan 275 works
- 5 Italy 184 works
- 6 Germany 144 works
- 7 France 126 works
- 8 United Kingdom 124 works
- 9 Brazil 92 works
- 10 South Korea 90 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Neurofibromatosis and Schwannoma Cases research?
By volume in 2022–2025, Neurological Surgery publishes the most Neurofibromatosis and Schwannoma Cases research, followed by All India Institute of Medical Sciences and Mayo Clinic.
By volume, 2022–2025
- 1 Neurological SurgeryUnited States 29 works
- 2 All India Institute of Medical SciencesIndia 27 works
- 3 Mayo ClinicUnited States 19 works
- 4 Johns Hopkins UniversityUnited States 18 works
- 5 Harvard UniversityUnited States 15 works
- 6 Massachusetts General HospitalUnited States 15 works
- 7 Mohammed V UniversityMorocco 14 works
- 8 University of California, Los AngelesUnited States 14 works
- 9 The University of Texas MD Anderson Cancer CenterUnited States 13 works
- 10 Washington University in St. LouisUnited States 13 works
Who are the leading researchers in Neurofibromatosis and Schwannoma Cases?
The most-cited researchers publishing on Neurofibromatosis and Schwannoma Cases include David N. Louis, Michael Weller and Andreas von Deimling.
- 1 David N. Louis United States 2.7k citations
- 2 Michael Weller Switzerland 2.7k citations
- 3 Andreas von Deimling Germany 2.4k citations
- 4 Alexander J. Lazar United States 2.3k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Neurofibromatosis and Schwannoma Cases research done?
The largest centres of Neurofibromatosis and Schwannoma Cases research in 2022–2025 are Tokyo (Japan), Beijing (China), New York (United States) and Shanghai (China). Among places with at least 20 works in it, it is an unusually large share of all research in Rockville Centre.
Largest cities, 2022–2025
Where it is the local speciality
- Rockville CentreUS · 29.3 works51×
Location quotient: how much more of its research is in Neurofibromatosis and Schwannoma Cases than the world average.
Where is the best place to study Neurofibromatosis and Schwannoma Cases?
Among universities, judged by research, Johns Hopkins University, Washington University in St. Louis and All India Institute of Medical Sciences score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Johns Hopkins UniversityUnited States | 50.1 | 15.8% | 4.3× | 18 | +16.7% |
| 2 | Washington University in St. LouisUnited States | 49.9 | 21.9% | 4.7× | 13 | -9.0% |
| 3 | All India Institute of Medical SciencesIndia | 49.3 | 1.9% | 11.2× | 27 | +35.6% |
| 4 | Harvard UniversityUnited States | 48.8 | 14.9% | 3.0× | 15 | +61.2% |
| 5 | Icahn School of Medicine at Mount SinaiUnited States | 40.7 | 5.3% | 5.2× | 10 | +207.7% |
| 6 | University of California, San FranciscoUnited States | 38.9 | 10.9% | 5.0× | 12 | +17.5% |
| 7 | University of California, Los AngelesUnited States | 38.0 | 12.2% | 3.7× | 14 | +19.5% |
| 8 | Mohammed V UniversityMorocco | 37.1 | 0.0% | 8.8× | 14 | +50.0% |
| 9 | Mohamed I UniversityMorocco | 35.2 | 0.0% | 13.3× | 8 | — |
| 10 | Capital Medical UniversityChina | 35.1 | 7.6% | 5.7× | 13 | +35.6% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Neurofibromatosis and Schwannoma Cases research growing?
Output in 2018–2022 was 22% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Neurofibromatosis and Schwannoma Cases.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.